INTENSITY THERAPEUTICS (INTS) Stock News

Intensity Therapeutics (Nasdaq: INTS) reported second quarter 2026 results and a business update. Research and development expenses were $1.8 million versus $1.5 million a year ago, and general and administrative expenses were $1.3 million versus $1.2 million. Net loss widened to $3.0 million from $2.5 million, with six‑month net loss at $5.4 million versus $5.9 million in 2025.

As of June 30, 2026, cash and cash equivalents were $9.5 million. The company established a $60 million at‑the‑market facility in March 2026, raising net proceeds of $1.6 million in Q2 and an additional $1.3 million thereafter. Intensity initiated activities to resume enrollment at selected U.S. sites in its Phase 3 INVINCIBLE‑3 soft tissue sarcoma study under an FDA‑reviewed amended protocol. In the Phase 2 INVINCIBLE‑4 TNBC study, patient treatment restarted with an updated dosing regimen; early data from 14 patients showed a 71% pathological complete response rate with INT230‑6 plus standard of care versus 42% with standard of care alone and a 44% reduction in grade 3 adverse events.

Intensity Therapeutics (Nasdaq: INTS), a late-stage clinical biotechnology company developing novel intratumoral cancer therapies using its proprietary non-covalent conjugation technology, will report second quarter 2026 financial results for the period ended June 30, 2026 before the market opens on August 11, 2026.

According to Intensity Therapeutics, company management will host a conference call and live webcast at 8:00 a.m. Eastern Time on August 11 to review the results and provide a corporate update. Investors can join via domestic dial-in (866) 652-5200, international dial-in (412) 317-6060, or the webcast URL provided. An archived webcast replay will be available shortly after the call.

Intensity Therapeutics (Nasdaq: INTS) announced the restart of patient treatment and first new dosing of INT230-6 in the randomized, open-label Phase 2 INVINCIBLE-4 presurgical triple-negative breast cancer (TNBC) trial in Switzerland. The study compares INT230-6 given before standard-of-care neoadjuvant immuno-chemotherapy (SOC) versus SOC alone in two cohorts.

The primary endpoint is pathological complete response (pCR) in the primary tumor and affected lymph nodes, with cohorts evaluated against a null hypothesis pCR rate of ≤0.6. The trial reopened after a pause to assess skin irritation, following a March 2026 protocol amendment to use a slightly lower drug-to-tumor volume ratio and a single INT230-6 injection. Before the pause, 14 patients were treated; those receiving INT230-6 prior to SOC reported a favorable trend toward fewer grade 3 or higher and immune-related adverse events versus SOC alone. The study is expected to enroll an additional 47 patients in Switzerland and France.

Intensity Therapeutics (Nasdaq: INTS) issued a mid‑year 2026 update on late‑stage development of INT230-6, its intratumoral cancer therapy. Key items include progress in Phase 2/3 breast cancer and Phase 3 soft tissue sarcoma trials, peer‑reviewed data in advanced tumors, active partnering discussions and expanded funding capacity via a $60 million at‑the‑market facility.

More than 200 patients have received INT230-6 in completed studies, and preliminary presurgical triple‑negative breast cancer data showed higher pathological complete responses and fewer severe adverse events versus standard of care.

Intensity Therapeutics (Nasdaq: INTS), a late-stage clinical biotechnology company developing proprietary intratumoral cancer therapies, has been named Cancer Treatment Technology Innovator of the Year 2026 – USA in GHP Magazine's Healthcare & Pharmaceutical Awards.

The judging panel cited Intensity's non-covalent drug-conjugation platform, encouraging clinical outcomes in advanced cancers with few options, and INT230-6's potential to reduce tumor burden and trigger systemic anticancer immune responses with limited off-target toxicity.

Intensity Therapeutics (Nasdaq: INTS) reported Q1 2026 results and a corporate update. Cash and cash equivalents were $10.2 million as of March 31, 2026. Preliminary INVINCIBLE-4 results showed pCR 71.4% with INT230-6 versus 33% SOC in a small sample, and 44% fewer grade ≥3 adverse events. Swissmedic approved resuming enrollment on March 26, 2026; the company plans to resume INVINCIBLE-4 enrollment in Q2 2026 and limited INVINCIBLE-3 U.S. sites by Q3 2026. First-quarter R&D was $1.2M, G&A $1.3M, and net loss $2.4M. A $60M ATM facility was established in March 2026.

Intensity Therapeutics (Nasdaq: INTS) was named a Platinum winner in the 2026 Pinnacle Awards for Healthcare in the Innovator in Biotech Solutions category on April 15, 2026.

The recognition highlights Intensity's intratumoral injection platform and lead investigational candidate INT230-6, a non-covalent drug-conjugation therapy combining cisplatin, vinblastine sulfate, and a penetration enhancer to improve tumor drug dispersion and immune recognition.

Intensity Therapeutics (Nasdaq: INTS) reported 2025 year-end results and a corporate update on March 27, 2026. The company raised over $20 million in 2025 and held $11.9 million cash, with a runway into Q2 2027. Key clinical highlights include IT-01 publication showing a 75% disease control rate and median overall survival of 11.9 months, and INVINCIBLE-4 preliminary data showing a 71.4% pCR in INT230-6 pre-SOC patients versus 33% SOC alone. Swissmedic approved resumption of INVINCIBLE-4 enrollment on March 26, 2026.

Intensity Therapeutics (Nasdaq: INTS) announced a strengthening of its intellectual property portfolio with the issuance in December 2025 of US Patent No. 12,496,345, titled "A Method of Treating Cancer."

According to the company, this brings the portfolio to four U.S. patents with one U.S. application pending, patent protection across 41 countries, and a European patent validated in 27 countries. The company highlighted registered trademarks, know-how, and ongoing IP generation to protect its intratumoral drug‑conjugation technology and lead compound INT230‑6.